<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059318</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001X2201</org_study_id>
    <nct_id>NCT01059318</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis</brief_title>
  <official_title>An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is an exploratory study. The purpose of the study is to determine whether escalating
      doses of RAD001 (everolimus) is safe and effective in patients with Lymphangioleiomyomatosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess safety, pharmacokinetics (PK) and pharmacodynamics (PD), Measure: Safety (vital signs, ECGs, safety labs, AEs), PK (concentration of everolimus), PD (serum VEGF-D)</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of everolimus Measure: improvement in pulmonary function (FVC)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of everolimus Measure: improvement in other measures of pulmonary function (FEV-1, lung volumes (TLC, TGV, RV), DLCO)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of everolimus Measure: improvement in exercise capacity (6-minute walk test), and change in O2 saturation (with supplemental oxygen unchanged)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Lymphangioleiomyomatosis</condition>
  <arm_group>
    <arm_group_label>RAD001 2.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RAD001 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RAD001 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>RAD001 2.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>RAD001 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>RAD001 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged &gt;/= 18 years with a diagnosis of LAM

          -  Pulmonary function abnormalities as follows:

          -  FEV1 of ≤ 80% of the predicted value following administration of a standard dose of a
             short acting β2-agonist (*200 µg Salbutamol, measured between 10 and 15 minutes of
             inhalation) OR

          -  FEV1 &lt; 90% of the predicted value of bronchodilator following administration of a
             standard dose of a short acting β2-agonist (*200 µg Salbutamol, measured between 10
             and 15 minutes of inhalation) and DLco (uncorrected) &lt;80% predicted.

          -  Female patients including those of childbearing potential will be included in this
             study.

          -  Negative pregnancy test at screening and baseline

        Exclusion Criteria:

          -  FEV1&lt;50% of predicted post-bronchodilator.

          -  Change in FVC (ml) &gt; ± 15% of screening value at baseline visit (not less than 14d
             after screening visit).

          -  Use of any medicine containing estrogen in the 4 months prior to the screening visit
             and for the duration of the study

          -  Significant hematologic, renal, hepatic laboratory abnormality or amylase &gt; 1.5x the
             upper limit of the normal range at the screening or baseline visits

          -  Fasting blood glucose &gt; 126mg/dl or random blood glucose &gt;200mg/dl at screening and/or
             baseline

          -  Recent surgery (involving entry into a body cavity or requiring sutures) within 2
             months of the screening visit or any evidence of unhealed surgical wound.

          -  Uncontrolled hyperlipidemia (defined as persistent elevation of total cholesterol or
             triglycerides &gt;6.5nM/L) or a history of clinical atherosclerotic disease including
             heart attack, angina, peripheral vascular disease or stroke.

          -  Previous organ transplantation

          -  Inability to give informed consent

          -  Inability to perform pulmonary function or 6 minute walk tests and imaging assessments

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for LAM Research and Clinical Care</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati, Department of Internal Medicine, Pulmonary, Critical Care &amp; Sleep Medicine,</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grosshansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <last_update_submitted>October 22, 2012</last_update_submitted>
  <last_update_submitted_qc>October 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphangioleiomyomatosis,</keyword>
  <keyword>High Resolution CT scan,</keyword>
  <keyword>chest x-ray,</keyword>
  <keyword>6 minute walk test,</keyword>
  <keyword>pulse oximetry,</keyword>
  <keyword>renal MRI,</keyword>
  <keyword>Pikometer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphangioleiomyomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 14, 2013</submitted>
    <returned>August 30, 2013</returned>
    <submitted>October 23, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>January 17, 2014</submitted>
    <returned>January 29, 2014</returned>
    <submitted>March 28, 2014</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>February 13, 2017</submitted>
    <returned>April 3, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

